INTRODUCTION
Increasing evidence supports the involvement of inflammation in the pathogenesis of atherosclerosis [1, 2] . One common feature of the inflammatory response is the presence of abundant monocyte/macrophages in all stages of atherogenesis. The infiltration of monocytes into the vascular wall and their transformation into lipid-laden foam cells characterize early atherogenesis. Macrophages are also present in more advanced human atherosclerotic plaques and can produce many mediators that may contribute to lesion formation and progression. Macrophage survival and proliferation are controlled by a group of glycoprotein molecules known as CSFs, such as M-CSF. Macrophages and endothelial cells (EC) are rich sources of M-CSF [3] . Human and rabbit atherosclerotic lesions contain increased levels of M-CSF protein and mRNA compared with normal artery tissue [4 -6] . In the dietary and apolipoprotein E (apoE) knockout models of atherosclerosis, M-CSF deficiency resulted in significantly reduced macrophages in the lesion and in decreased atherosclerotic lesions [7] [8] [9] . Also, M-CSF has been shown to accelerate neointimal formation after wiremediated vascular injury in the femoral artery of wild-type mice [10] .
C-reactive protein (CRP), the prototypic marker of inflammation, has been shown in numerous studies to predict cardiovascular events [11, 12] . In addition to being a risk marker, several lines of evidence indicate that CRP, by enhancing inflammation, oxidative stress, and procoagulant activity, may play a role in atherothrombosis [11] [12] [13] [14] . Previously, CRP has been shown to up-regulate adhesion molecules, chemokines, plasminogen activator inhibitor-1, and cytokines and to downregulate endothelial NO synthase (eNOS) and prostacyclin release from human aortic EC (HAEC) [11] [12] [13] [14] [15] [16] . In monocytemacrophages, CRP augments reactive oxygen species, tissue factor, cytokines, matrix metalloproteinase (MMP), and oxidized low-density lipoprotein uptake [11] [12] [13] [14] [15] [16] [17] [18] . However, the effect of CRP on M-CSF release and on cell proliferation has not been examined previously and will be the focus of this study.
In this report, we demonstrate for the first time that CRP induces M-CSF release via up-regulation of NF-B and results in increased macrophage proliferation.
MATERIALS AND METHODS
Human CRP was purified from human ascitic/pleural fluids as described by Du Clos et al. [19] . We have shown that our in-house-purified, dialyzed CRP mediates its inflammatory effects in TLR4 knocked-down cells, providing further cogent data that CRP-mediated effects are not a result of endotoxin contamination [20] . Ficoll and piceatannol (Syk kinase inhibitor) were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
HAEC (Cambrex, East Rutherford, NJ, USA) were grown in endothelial medium supplemented with growth factor (EGM-MV) in a humidified incubator at 37°C under 5% CO 2 , 95% air, and used between Passages 3 and 5. For the initial experiments, cells were grown in 12-well plates. Upon reaching 80% confluency, the cells were incubated with CRP (6.25, 12.5, 25, and 50 g/ml) or boiled CRP for 12-15 h. Monomeric CRP (mCRP) was prepared as described previously [21] , and HAEC were incubated with mCRP (12.5, 25, and 50 ug/ml) for 15 h. However, for all subsequent experiments involving mechanistic insights, native CRP at 25 g/mL concentration was used. Conditioned media (CM) from HAEC treated with CRP (25 g/mL; EC-CM) were collected after the 12-to 15-h incubation for use in the human monocyte-derived macrophage (HMDM) proliferation assays. Supernatants and cells were stored for M-CSF assays at -20°C. EC-CM without CRP was used as control.
Following Ficoll separation, monocytes were obtained from blood of normal human volunteers by negative magnetic separation as described previously [22] . The Institutional Review Board of University of California Davis (Sacramento, CA, USA) approved the protocol. Using this technique in our laboratory, we have shown that at least 86% of cells are CD14-positive by flow cytometry. HMDM were obtained as described previously and used on Day 7 of culture. HMDM were incubated with CRP (0 -50 g/mL) in the absence or presence of inhibitors. In proliferation assays, HMDM were incubated with CRP-treated EC-CM (2.5-10%) for 24 h. Following treatment, supernatants and cells were stored for M-CSF assays. M-CSF release was quantitated by ELISA using reagents from R&D Systems (Minneapolis, MN, USA). M-CSF expression was also assessed by flow cytometry using fluorochrome-labeled antibodies to M-CSF and appropriate isotype controls. RNA was obtained from cells using Trizol, and RT-PCR for M-CSF mRNA was performed as described previously [15] .
BrdU proliferation assays were carried out using reagents from Calbiochem (Gibbstown, NJ, USA). Briefly, BrdU, a thymidine analog, is incorporated into newly synthesized DNA strands of actively proliferating cells. Following partial denaturation of double-stranded DNA, BrdU is detected immunochemically, allowing the assessment of the population of cells, which are actively synthesizing DNA. During the final 12 h of culture, BrdU is added to wells of the plate and is incorporated into the DNA of dividing cells. Cells are fixed and permeabilized, and the DNA is denatured. Anti-BrdU mAb is added for 1 h, unbound antibody is then washed away, and HRP-conjugated goat anti-mouse is added, followed by the substrate tetramethylbenzidine, and absorbance at 450 nm is read.
Transfection with dominant-negative IB vector or control vector was performed as described previously [17, 18, 23] . Previously, we have shown that this transfection compared with control vector results in decreased IB kinase (IKK) by Western blotting and decreased CRP-induced NF-B binding by EMSA [23, 24] . Also, small interfering (si)RNA to CD32 or CD64, obtained from Ambion (Austin, TX, USA), was transfected using siPORTamine transfection reagents as described previously [15, 17, 18] .
Statistical analysis
All experiments were performed at least three times in duplicate. The comparisons among group means were analyzed using ANOVA. The experimental results are presented as the means Ϯ SD. Paired t-tests were used to compute differences in the variables, and the level of significance was set at P Ͻ 0.05.
RESULTS
The effect of CRP in M-CSF was tested in HAEC and HMDM. Incubation of HAEC with CRP resulted in a significant dosedependent induction of M-CSF release (Fig. 1A) and cellular M-CSF by flow cytometry (Fig. 1B) . Furthermore, CRP treatment of EC resulted in an increase in M-CSF mRNA (Fig. 1C) . Also, CRP had similar effects of inducing M-CSF protein and mRNA from HMDM (Fig. 1, A-C) . Boiled CRP failed to have any significant effect. Furthermore, addition of polymixin B failed to suppress CRP-augmented M-CSF. These results indicate CRP-specific induction of M-CSF release from HAEC and
g/mL, 299Ϯ101 pg/mg protein; CRP 50 g/mL, 509Ϯ133 pg/mg protein; mCRP 50 g/mL, 331Ϯ121 pg/mg protein; nϭ4; *, PϽ0.05, by ANOVA, native vs. mCRP).
We next treated HMDM with CM from HAEC treated with CRP (25 g/mL; EC-CM). EC-CM also caused significant up-regulation of M-CSF from HMDM ( Fig. 2A) . EC-CM without CRP treatment was used as control and failed to upregulate M-CSF release from HMDM. Also, as an index of the biological activity of M-CSF, macrophage proliferation was assessed. There was significant increase in BrdU uptake, i.e., increased macrophage proliferation following incubation with CRP (25 g/ml) or with 5% EC-CM (Fig. 2B) . To show that the proliferation was indeed a result of M-CSF, HMDM were incubated with EC-CM, pretreated with M-CSF antibody or an irrelevant antibody (IgG). Pretreatment with antibody to M-CSF but not irrelevant antibody resulted in a significant blockade of M-CSF release and HMDM proliferation (Fig. 2B) . Of note, treatment with M-CSF antibody did not affect the M-CSF-ELISA results. We also examined cell number as an index of proliferation, and there was a significant increase in the number of macrophages in wells with CRP compared with control (data not shown). These data support a potential paracrine mechanism between HAEC and HMDM in human atheroma.
To gain mechanistic insights, as the M-CSF promoter has been shown previously to have NF-B-binding elements, we transfecting HAEC with a dominant-negative IB. In addition to abolishing NF-B activity (as shown previously; refs. [22, 25] ), it resulted in a significant decrease in M-CSF protein (Fig. 3A), mRNA (Fig. 3B), and subsequent proliferation (Fig.  3C) . Control vector failed to have any effect (Fig. 3) .
In HAEC and HMDM, CRP binds to the Fc␥Rs CD32 and CD64 and mediated its biological effects. Preincubation of HAEC with antibodies to CD32 and CD64, but not CD16, resulted in a significant decrease in CRP-induced M-CSF release (Fig. 4A) and subsequent HMDM proliferation (Fig.  4B ). CD32 antibodies resulted in an 82% reduction, and CD64 antibodies resulted in 53% inhibition of CRP-induced M-CSF (Fig. 4, A and B) . Irrelevant IgG antibodies failed to have any effect on CRP-induced M-CSF (data not shown). These experiments were confirmed by transfecting HAEC with siRNA to CD32 and to CD64 (Fig. 4, C and D) . CD32 signals through the activation of Syk kinase; thus, we tested the effect of piceatannol, a Syk kinase inhibitor. Piceatannol was able to inhibit CRP-induced M-CSF release from HAEC by 77%. These results indicate that CRP induces M-CSF from HAEC and HMDM transcriptionally via induction of NF-B, and these effects appear to be mediated largely via activation of CD32 and partly via CD64 activation.
DISCUSSION
The infiltration of monocytes into the intima and their transformation into lipid-laden foam cells characterize early atherogenesis [6] . Macrophages are also present in more advanced human atherosclerotic plaques and can produce many mediators that may contribute to lesion formation and progression [24] . M-CSF enhances the proliferation and differentiation of monocyte progenitors and is required for the survival and activation of mature monocytes and macrophages [7] [8] [9] . M-CSF mRNA has been shown to be several folds higher in human atheromata compared with that found in nonatherosclerotic arteries and veins. Mice deficient in M-CSF and apoE have elevated cholesterol levels but are protected from atherosclerosis. In the dietary and apoE knockout models, M-CSF deficiency resulted in significantly reduced atherogenesis [7] [8] [9] . M-CSF has emerged as one of the strongest risk factors for adverse outcomes in patients with stable angina [26 -29] . Significantly elevated M-CSF is a harbinger of acute coronary syndrome (ACS) in these patients. Serum M-CSF levels determined 6 weeks after discharge in patients with severe, unstable angina have been demonstrated to be strong predictors of cardiac events during a 2-year follow-up [27] .
Various clinical investigations support the concept that high levels of serum CRP are associated with increased risk for cardiovascular disease [10 -12] . CRP immunoreactivity is also reported to be significantly higher in the plaque of patients with unstable angina pectoris than in those with stable angina pectoris. Importantly, the colocalization of CRP and macrophages has been demonstrated in advanced human atherosclerotic plaque [30] . Also, leukocyte infiltration into plaques has been found to be actively associated with acute coronary events, and raised M-CSF levels in patients with unstable angina are strongly predictive of long-term outcome [26 -29] . CRP levels are also increased in patients with unstable angina and ACS [30 -32] . In patients with chronic coronary artery disease, the prognostic value of M-CSF is independent and complementary to that of CRP [26 -29] . However, there is a paucity of data examining the direct effect of CRP on M-CSF and on subsequent macrophage proliferation.
In the present study, CRP induced the release of M-CSF from HAEC and HMDM at a CRP concentration of 12.5-50 g/ml. Importantly, Ridker and Cook [31] have shown that CRP levels Ͼ20 g/mL predict future cardiovascular events. Also, patients with ACS have high levels of circulating CRP (18 -90 mg/L) [31, 32] . Therefore, it is likely that local CRP levels in atherosclerotic lesions from circulation or its local synthesis by cells present in arterial lesions, as we and others have shown previously, result in increased M-CSF release and subsequent proliferation and migration of monocytes in the intima. Also, these data support a potential paracrine mechanism between HAEC and HMDM in human atheroma. It is also important to point out that native, unlike mCRP exists in human plasma and atheroma, where the calcium concentration of Ͼ2 mM keeps it in the native, pentameric state. The majority of researchers in the CRP area in fact questions the existence of mCRP, as its presence has not been documented in human plasma or atheroma [12, 33, 34] . Furthermore, recent studies in fact indicate that mCRP may be antiatherogenic in vivo [25, 35] . As we have reported previously for other biomediators, in the present report also, we show that native CRP is more potent than mCRP in stimulating M-CSF release [21] .
Regarding mechanistic insights, CRP induced the release of M-CSF and subsequent HMDM proliferation via up-regulation of NF-B. Previously, we and others [17, 18, 23] have shown that CRP up-regulates NF-B activity directly in HAEC and macrophages using different techniques, EMSA, p65 activity in nuclear extracts, as well as Western blotting for p65 and IKK␤. CRP up-regulates M-CSF at the mRNA level. Previously, modified lipoproteins have been shown to induce M-CSF mRNA and protein via activation of a functional NF-Bbinding site on the M-CSF promoter [36] . Furthermore, human cardiac cells constitutively express M-CSF [37] . This expression of M-CSF in the human heart was down-regulated by dominant-negative IB transfection and resulted in reduced macrophage survival and differentiation. These observations lend support to our data showing decreased M-CSF and HMDM proliferation with blockade of NF-B using dominant-negative IB.
Immunocytochemical detection of Fc␥Rs in human atherosclerotic lesions has been demonstrated [38] . We and others [17, 18, 39 -41] have shown previously that blocking of CD32/ CD64 in HAEC and HMDM abrogates effects of CRP. In addition, in human monocytes and U937 histiocytes, CRP has been shown to induce CCR2 expression via CD64 and MMP-1 expression via CD32. In this paper, we report that CRP mediated M-CSF release, and subsequent macrophage proliferation can be blocked by antibodies to CD32 and CD64 but not CD16; this was confirmed using siRNA. Previously in murine macrophages, CD64 has been shown to regulate M-CSF mRNA transcriptionally [42] . In this study, we show that blockade of CD32 or CD64 abrogated CRP-induced M-CSF; also, the Syk kinase inhibitor, through which CD32 and CD64 signal, also abrogated CRP-induced M-CSF release.
Thus, we show in HAEC and HMDM that CRP augments M-CSF release and biological activity. Release of M-CSF from HAEC results in increased proliferation of HMDM. Furthermore, CRP-induced M-CSF release and macrophage proliferation appear to be mediated via activation of NF-B and the Fc␥Rs CD32 and CD64. These data, showing that CRP induces M-CSF, combined with the earlier demonstrated effects of CRP on inhibiting eNOS and up-regulating VCAM, IL-8, and MCP-1 and monocyte-EC adhesion under static and shear flow conditions, collectively support a pivotal role for CRP on monocyte recruitment and proliferation (Fig. 5) .
